Hosp

International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis

- ENDORSE Global Findings Highlight the Need to UrgentlyImplement Hospital-Wide Strategies to Optimize VTE Management:Systematically Assess Patient Risk for VTE and Provide Appropriateprophylaxis to Prevent VTE Venous thromboembolism (VTE) risk is high among hospitalpatients and most of these at-risk patients are not pro...

AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis

AM Pharma Continues Its Success with Positive Phase IIa ClinicalTrial Results First clinical Results Confirm Potential New Application of KeyProduct in AM-Pharma's Pipeline BUNNIK, The Netherlands, July 9, 2007-AM-Pharma B.V., thebiopharmaceutical company developing novel therapeutics to treatinfectious and inflammatory diseases, today announced the positiveclinical results of its...

Common Preterm Labor Drug Has More Side Effects Than Alternative, Finds Study from Packard Children's Hospital and Stanford

STANFORD, Calif.--(BUSINESS WIRE)--Jun 29, 2007 - The drug mostcommonly used to arrest preterm labor, magnesium sulfate, is morelikely than another common treatment to cause mild to serious sideeffects in pregnant women, according to a study from researchers atLucile Packard Children's Hospital and Stanford University Schoolof Medicine. Their findings suggest that, since the effectivenessof...

Phosphagenics Announces Positive Proof of Concept Results from Studies Utilizing Company's Dermal Drug Delivery Technology

MELBOURNE, Australia, June 25, 2007 /PRNewswire-FirstCall/ --Phosphagenics Limited (AIM: PSG) announced today positive resultsfrom pre-clinical studies of its TPM-02 dermal drug deliverytechnology formulated with retinoic acid, a leading topicaltreatment for severe acne and an active ingredient used inanti-aging cosmetics. The proof of concept studies showed a three-fold increase i...

Interim Data From RECORD Study Show No Significant Difference Between Avandia and Standard Therapy in Risk of Cardiovascular Hospitalization or Death

"Patients and physicians should find these data reassuring" PHILADELPHIA, June 05, 2007 /PRNewswire-FirstCall/ --GlaxoSmithKline said today that findings from an interim analysisof RECORD (Rosiglitazone Evaluated for Cardiac Outcomes andRegulation of glycemia in Diabetes), a prospective clinical trialdesigned specifically to determine cardiovascular outcomes in morethan 4,400 patients wit...

New Study Shows Doxorubicin Plus Paclitaxel Followed by Weekly Paclitaxel as Adjuvant Therapy for High Risk Breast Cancer Warranted in Place of Doxorubicin Plus Cyclophosphamide Followed by Paclitaxel

22 US Oncology Affiliated Physicians Participate in ASCOProceedings HOUSTON, June 04, 2007 /PRNewswire/ -- A leading cancerresearcher affiliated with the US Oncology Research Networkpresented findings from a randomized, multicenter phase III trialthat compared the disease-free survival (DFS) obtained with tworegimens of adjuvant therapy for patients with high-risk breastcancer. Th...

New Analysis of Data Shows Treatment With Abbott's Humira (Adalimumab) Significantly Reduced Disease-Related Hospitalization for Patients with Crohn's Disease

HUMIRA Data Showed 57 Percent Reduction in Risk of Hospitalizationfrom Crohn's Disease vs. Placebo at One Year ABBOTT PARK, Ill., May 22, 2007 /PRNewswire-FirstCall/ -- Abbotttoday announced results from a post-hoc analysis of a pivotal studypresented at the Digestive Disease Week annual meeting inWashington, D.C. showing patients with moderate to severely activeCrohn's disease treated wi...

Nektar Threraputics Announces Phase 2a Clinical Results Regarding the use of NKTR-061 (Inhaled Amikacin) to Treat Gram-Negative Hospital-Acquired Pneumonia Presented at the Annual American Thoracic Society International Conference

SAN FRANCISCO--(BUSINESS WIRE)--May 21, 2007 - Medicalprofessionals seeking to treat the serious and growing problem ofhospital-acquired gram-negative pneumonia may have a new weapon:NKTR-061 (inhaled-amikacin), which is a product candidate beingdeveloped by Nektar Therapeutics (Nasdaq:NKTR). Results of a Phase 2a clinical trial evaluating the use ofNKTR-061 (Inhaled Amikacin) to treat me...

Phosphagenics to Commence Phase 1b Transdermal Insulin Clinical Trial in Second Quarter

MELBOURNE, Australia, May 03, 2007 /PRNewswire-FirstCall/ --Phosphagenics Limited (AIM: PSG) announced today that the Companyintends to initiate a Phase 1b clinical trial to demonstrate theefficacy and safety of the improved formulation of its transdermalinsulin product, TPM-02/Insulin, containing long-acting insulin.The trial is expected to commence in the second quarter of2007....

Six Important Things to Know About Preventing Hospital Infections

Infection Control Professional Offers Patient Tips to Guard AgainstHospital Infections KANSAS CITY, Kan., April 02, 2007 /PRNewswire/ -- Hospitalinfections are among the top ten leading causes of death in theUnited States, according to the Centers for Disease Control. Thereare countless stories about patients who go into hospitals withminor conditions and leave under much graver circumsta...

ACC Presentation Indicates Interleukin-1 Gene Variants Determine Increased Risk for Coronary Artery Disease from Oxidized Phospholipids

WALTHAM, Mass.--(BUSINESS WIRE)--Mar 27, 2007 - InterleukinGenetics, Inc. (AMEX:ILI) and collaborators at the University ofCalifornia San Diego today reported at the American College ofCardiology annual meeting that associations between coronary arterydisease (CAD) and both oxidized phospholipids (OxPL) and Lp(a)levels appear to be dependent on pro-inflammatory variants of theinterleukin-1...

Lipitor Significantly Lowered Hospitalization Costs for Patients with Heart Disease, Two New Analyses Show

NEW ORLEANS--(BUSINESS WIRE)--Mar 27, 2007 - Pfizer announced todaythat Lipitor(R) (atorvastatin calcium) Tablets (80 mg) loweredhospitalization costs by significantly reducing the risk ofcardiovascular events in patients with heart disease, according totwo separate economic analyses. The data were presented at theannual meeting of the American College of Cardiology. "One of these analyse...

Hospitalization Rates for Coronary Artery Disease Decline in the U.S.

EVANSTON, Ill., March 20, 2007 /PRNewswire/ -- Treatment ofcoronary artery disease (CAD) appears to be shifting away from theinpatient setting, according to a study published today in TheAmerican Journal of Cardiology. U.S. hospitalization rates for heart attacks (acute myocardialinfarctions) declined 10.6 percent from 2002 to 2005, possibly dueto broader use of preventive treatmen...

AM-Pharma Announces Positive Results of a Phase IIa Clinical Trial with Alkaline Phosphatase in Acute Renal Failure

Results expand potential application of key product inAM-Pharma's pipeline BUNNIK, The Netherlands, 14 March, 2007. AM-Pharma B.V., thebiopharmaceutical company developing novel therapeutics to treatinfectious and inflammatory diseases, today announced positiveresults in patients with Acute Renal Failure. The patients involvedwere a subgroup of a Phase IIa trial with Alkaline Phosp...